» Articles » PMID: 34532488

A Narrative Review of Tumor Heterogeneity and Challenges to Tumor Drug Therapy

Overview
Journal Ann Transl Med
Date 2021 Sep 17
PMID 34532488
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To accurately evaluate tumor heterogeneity, make multidimensional diagnosis according to the causes and phenotypes of tumor heterogeneity, and assist in the individualized treatment of tumors.

Background: Tumor heterogeneity is one of the most essential characteristics of malignant tumors. In tumor recurrence, development, and evolution, tumor heterogeneity can lead to the formation of different cell groups with other molecular characteristics. Tumor heterogeneity can be characterized by the uneven distribution of tumor cell subsets of other genes between and within the disease site (spatial heterogeneity) or the time change of cancer cell molecular composition (temporal heterogeneity). The discovery of tumor targeting drugs has dramatically promoted tumor therapy. However, the existence of heterogeneity seriously affects the effect of tumor treatment and the prognosis of patients.

Methods: The literature discussing tumor heterogeneity and its resistance to tumor therapy was broadly searched to analyze tumor heterogeneity as well as the challenges and solutions for gene detection and tumor drug therapy.

Conclusions: Tumor heterogeneity is affected by many factors consist of internal cell factors and cell microenvironment. Tumor heterogeneity greatly hinders effective and individualized tumor treatment. Understanding the fickle of tumors in multiple dimensions and flexibly using a variety of detection methods to capture the changes of tumors can help to improve the design of diagnosis and treatment plans for cancer and benefit millions of patients.

Citing Articles

Immunotherapy-induced microsatellite instability status shift in recurrent perihilar cholangiocarcinoma: A case report.

Yu H, Deng T, Liu H Hum Vaccin Immunother. 2025; 21(1):2471226.

PMID: 39996476 PMC: 11864312. DOI: 10.1080/21645515.2025.2471226.


Impact of G1 phase kinetics on the acquisition of stemness in cancer cells: the critical role of cyclin D.

Ahmadi Y, Faiq T, Abolhasani S Mol Biol Rep. 2025; 52(1):230.

PMID: 39951181 DOI: 10.1007/s11033-025-10351-3.


Role of bacteria in cancers and their therapeutic potential: Review of current knowledge.

Wawrety W, Kedziora A Iran J Basic Med Sci. 2025; 28(3):273-282.

PMID: 39906620 PMC: 11790194. DOI: 10.22038/ijbms.2024.77667.16798.


From Pioneering Discoveries to Innovative Therapies: A Journey Through the History and Advancements of Nanoparticles in Breast Cancer Treatment.

Basingab F, Alshahrani O, Alansari I, Almarghalani N, Alshelali N, Alsaiary A Breast Cancer (Dove Med Press). 2025; 17:27-51.

PMID: 39867813 PMC: 11761866. DOI: 10.2147/BCTT.S501448.


Investigation of Exome-Wide Tumor Heterogeneity on Colorectal Tissue-Based Single Cells.

Szakallas N, Kalmar A, Bartak B, Nagy Z, Valcz G, Linkner T Int J Mol Sci. 2025; 26(2).

PMID: 39859451 PMC: 11766235. DOI: 10.3390/ijms26020737.


References
1.
Dupont C, Armant D, Brenner C . Epigenetics: definition, mechanisms and clinical perspective. Semin Reprod Med. 2009; 27(5):351-7. PMC: 2791696. DOI: 10.1055/s-0029-1237423. View

2.
Schmid S, Gautschi O, Rothschild S, Mark M, Froesch P, Klingbiel D . Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). J Thorac Oncol. 2016; 12(4):681-688. DOI: 10.1016/j.jtho.2016.12.003. View

3.
Jia K, He Y, Dziadziuszko R, Zhao S, Zhang X, Deng J . T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer. Transl Lung Cancer Res. 2020; 8(6):895-906. PMC: 6976352. DOI: 10.21037/tlcr.2019.11.17. View

4.
West J, You L, Zhang J, Gatenby R, Brown J, Newton P . Towards Multidrug Adaptive Therapy. Cancer Res. 2020; 80(7):1578-1589. PMC: 7307613. DOI: 10.1158/0008-5472.CAN-19-2669. View

5.
Ramirez M, Rajaram S, Steininger R, Osipchuk D, Roth M, Morinishi L . Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat Commun. 2016; 7:10690. PMC: 4762880. DOI: 10.1038/ncomms10690. View